North America Custom Antibody Services Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

The North America custom antibody services market is projected to grow significantly, reaching approximately US$ 577.76 million by 2031, up from US$ 287.49 million in 2023, with an estimated compound annual growth rate (CAGR) of 9.1% from 2023 to 2031.

Executive Summary and Market Analysis

The custom antibody services market in North America is divided into three main regions: the United States, Canada, and Mexico. Several factors are driving the growth of this market, including the increasing adoption of advanced technologies, rising investments in drug discovery and development, strong government support for clinical research, and a surge in research activities in clinical diagnostics. Additionally, collaborations between government bodies and market players are promoting the use of custom antibodies in clinical diagnostics. The growing number of cancer and genomic research initiatives in the US and Canada, along with a focus on developing antibody-based therapeutics, are also contributing to market expansion. The demand for high-quality research tools to ensure data reproducibility further supports the growth of the custom antibody services market in North America.

Market Segmentation Analysis

The North America custom antibody services market can be segmented based on product type, service type, application, disease indication, source, and end user:

Product Type: The market is categorized into monoclonal, polyclonal, hybridoma, recombinant antibodies, and others. In 2023, monoclonal antibodies held the largest market share.
Service Type: This segment includes antibody discovery and development, antibody production services, and others, with antibody discovery and development leading in market share in 2023.
Application: The applications include immunohistochemistry, western blotting & immunoprecipitation (IP), ELISA, fluorescence-activated cell sorting, mass spectrometry, and others. ELISA was the most significant application in 2023.
Disease Indication: The market is segmented into oncology, infectious diseases, immunology, cardiovascular diseases, and others, with oncology being the largest segment in 2023.
Source: This includes chicken, rabbits, rats, guinea pigs, and mouse or humanized mice, with the latter holding the largest share in 2023. This segment is further divided into various platforms for monoclonal antibodies and other technologies.
End User: The end users include the life sciences industry, pharmaceutical and biotech companies, academic and research institutes, and contract research organizations, with the life sciences industry leading in market share in 2023.

Market Outlook

The FDA plays a crucial role in approving biosimilar products, which enhances patient care by providing more medication options at potentially lower costs. Recent approvals of biosimilars, such as Alymsys and Cimerli, have been significant in expanding treatment options. The increasing number of biosimilars approved by the FDA is expected to drive the growth of the custom antibody services market, as they can lower treatment costs and improve access to biologic therapies.

Country Insights

The North American custom antibody services market is primarily driven by the US, which accounted for the largest share in 2023. The rising incidence of infectious, chronic, and autoimmune diseases in the US is increasing the demand for custom antibody services. Cancer remains a leading cause of death, with over 1.9 million new cases diagnosed in 2022, and projections suggest around 2.0 million new diagnoses in 2024. Custom antibodies are essential in cancer treatment for detecting tumor-specific antigens and monitoring patient progress. The US market benefits from increased R&D efforts and the growing use of custom antibodies across various research fields, including oncology and immunology.

Company Profiles

Key players in the custom antibody services market include Thermo Fisher Scientific Inc., Sino Biological Inc., GenScript Biotech Corporation, Biochain Incorporated, R&D Systems, Inc., Kaneka Eurogentec S.A., Fortis Life Sciences, Precision Antibody, Biocytogen Pharmaceuticals, Abgenex, Creative Biolabs, Agilent Technologies, Bioklone, and Scantibodies Laboratory, Inc. These companies are employing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative solutions to their customers.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America custom antibody services market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in North America custom antibody services market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the custom antibody services market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution. Show more